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Abstract  
Objective: Aiming to delineate novel neuro-immune mechanisms for NGF/TrkA signalling in 
OA pain, we evaluated inflammatory changes in the knee joints following injection of 
monoiodoacetate (MIA) in mice carrying a TrkA receptor mutation (P782S; TrkA KI mice).  
Method: In behavioural studies we monitored mechanical hypersensitivity following intra-
articular MIA and oral prostaglandin D2 (PGD2) synthase inhibitor treatments. In 
immunohistochemical studies we quantified joint mast cell numbers, calcitonin gene-related 
peptide expression in synovia and dorsal root ganglia, spinal cord neuron activation and 
microgliosis. We quantified joint leukocyte infiltration by flow cytometry analysis, and PGD2 
generation and cyclooxygenase-2 (COX-2) expression in mast cell lines by ELISA and 
Western blot.  
Results:  In TrkA KI mice we observed rapid development of mechanical hypersensitivity and 
amplification of dorsal horn neurons and microglia activation 7 days after MIA. In TrkA KI 
knee joints we detected significant leukocyte infiltration and mast cells located in the vicinity 
of synovial nociceptive fibres. We demonstrated that mast cells exposure to NGF results in 
up-regulation of COX-2 and increase of PGD2 production. Finally, we observed that a PGD2 
synthase inhibitor prevented MIA-mechanical hypersensitivity in TrkA KI, at doses which 
were ineffective in WT mice. 
Conclusion: Using the trkA KI mouse model, we delineated a novel neuro-immune pathway 
and suggest that NGF-induced production of PGD2 in joint mast cells is critical for referred 
mechanical hypersensitivity in OA, probably through the activation of PGD2 receptor 1 in 
nociceptors: TrkA blockade in mast cells constitutes a potential target for OA pain.  
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Introduction 1 
 2 
The neurotrophin nerve growth factor (NGF) is constitutively produced and released by 3 
synovial fibroblasts in the joint and sensitizes nociceptive neurons that express TrkA receptors 4 
and innervate the joints1. Under inflammatory conditions, NGF expression is up-regulated by 5 
cytokines, and inflammatory cells such as mast cells release NGF2. Indeed, extracellular NGF 6 
levels are higher in inflamed joints and NGF blockade with both TrkA-IgG fusion protein and 7 
NGF monoclonal antibodies produces analgesic effects in preclinical settings3, 4. Relevantly, 8 
humanised monoclonal anti-NGF antibodies are effective analgesics in people with 9 
osteoarthritis joint pain5. However, unexpected side effects such as increased incidence of 10 
bone necrosis indicate that more studies are needed to understand NGF-mediated regulation 11 
of osteoarthritis (OA) pain.   12 
 13 
In this preclinical study we use intra-articular monoiodoacetate (MIA) injection as this OA 14 
model is associated with dose-dependent and rapid pain-like responses in the ipsilateral limb, 15 
which persists for several weeks. The ipsilateral joints display morphological changes of the 16 
articular cartilage and bone disruption, which are reflective of some aspects of patient 17 
pathology, as well as synovitis and macrophage infiltration3, 6. Furthermore, this model of OA 18 
reflects specific changes in the NGF/TrkA system as follows: i) the TrkA antagonist AR786 19 
shows both prophylactic and therapeutic anti-nociceptive efficacy in MIA rats3; ii) local intra-20 
articular injection of NGF in  MIA-knee joints facilitates the responses of spinal cord neurons to 21 
extension of the knee joint7. 22 
 23 
The most frequent types of immune cells found in people with OA joints are macrophages, T 24 
cells and mast cells8 TrkA receptors are expressed by mast cells and macrophages and their 25 
activation by NGF leads to up-regulation and release of inflammatory mediators, which 26 
sensitize joint nociceptors2.  27 
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 28 
With the aim to investigate neuro-immune mechanisms mediated by NGF/TrkA signalling in 29 
OA pain, we have examined the development of MIA-referred mechanical hypersensitivity and 30 
joint pathology in wild type and mice carrying a mutation in the TrkA receptor in which Proline 31 
782 is mutated to Serine. This TrkA mutation confers a defect on ubiquitination by Nedd4-2 32 
(E3 ubiquitin ligase) which leads to i) an increase in NGF-mediated signalling; ii) 33 
approximately 30% increase of dorsal root ganglia neurons; iii) increased sensitivity to noxious 34 
hot and cold, but not mechanical, stimuli; iv) enhanced behavioural response to intraplantar 35 
formalin and v) increased activation of spinal cord neurons after formalin9, 10. 36 
 37 
Method 38 
 39 
Animals. Studies were conducted in accordance with UK Home Office regulations, 40 
International Association for the Study of Pain and ARRIVE guidelines11.  Male and female 41 
TrkAP782S (TrkA KI) and wild type (WT) littermates of C57BL/6 background, aged 3-6 months 42 
old (25-35 g) were housed under a 12-hour light/dark cycle, with food and water available ad 43 
libitum. In all studies, experimental groups were randomized and an equal number of 3-6 44 
months old-female and -male transgenic mice was used and data combined.  Experiments 45 
were performed blind. 46 
 47 
Behavioural testing. Mechanical withdrawal thresholds were assessed by calibrated von Frey 48 
monofilaments (0.02-1g, North Coast Medical Inc.) application to the plantar surface of the 49 
hind paw. 50% paw withdrawal threshold (PWT) was determined according to the “up–down” 50 
method12.  51 
 52 
In the monoiodoacetate model mice received an intra-articular injection of either saline or 53 
0.7mg MIA (Sigma-Aldrich) in 10µL of sterile saline6. 54 
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 55 
Drug administration. A Tanezumab-like antibody (Levicept) or antibody control (IgG1, kappa 56 
Sigma-Aldrich, I5154), dissolved in sterile saline were administered subcutaneously at 57 
5mg/kg, every 5 days, starting from the day before MIA injections. HQL-79 (Tocris) was 58 
dissolved in 0.5% methylcellulose. HQL-79 (3 and 10mg/kg) or vehicle was administered by 59 
oral gavage.  60 
 61 
Immunohistochemistry. Seven days after MIA injection, mice were perfuse-fixed under 62 
terminal anaesthesia through the ascending aorta with heparinised saline followed by 4% 63 
paraformaldehyde fixative solution with 1.5% picric acid in phosphate buffer (0.1M, pH 7.4, 64 
PB). Sections from knee joints (30µm), lumbar spinal cord (20µm) and L3-L5 DRG (10µm) 65 
were incubated overnight with sheep anti–calcitonin gene-related peptide (CGRP, 1:500, Enzo 66 
Life Sciences). Spinal cord sections were incubated as follows: rabbit anti-c-Fos (1:1000, Cell 67 
Signaling Technology) followed by Alexa Fluor 488- or 546-conjugated antibodies (1:1000; 68 
Molecular Probes); rabbit anti– p-p38 (1:100, Cell Signaling Technology) and biotinylated 69 
secondary antibody (1:400 biotin donkey anti-rabbit, Jackson ImmunoResearch Labs); 70 
peroxidase containing avidin-biotin complex (1:200, Vector Laboratories)  and  biotinylated 71 
tyramide (NEN Life Science Products) which was detected with ExtrAvidin-FITC (1:500, 72 
Sigma-Aldrich); rabbit anti-Iba-1 (1:100 Wako Pure Chemical Industries Ltd.) followed by 73 
Alexa Fluor 546-conjugated antibody (1:1000; Molecular Probes). Knee joint sections were 74 
incubated with anti-cluster of differentiation 117 (CD117, 1:1000 R&D Systems) or anti–75 
calcitonin gene-related peptide (CGRP). In control experiments, no staining was visible when 76 
joint, spinal cord or DRG sections were processed for immunohistochemistry with omission of 77 
the primary antibody. All slides were mounted with Vectashield Mounting Medium containing 78 
nuclear marker 49,6-diamidino-2-phenylindole·2HCl (DAPI; Vector Laboratories), and 79 
visualized using a Zeiss Axioplan 2 fluorescent microscope (Zeiss). Acquisition parameters 80 
remained constant and unprocessed images were used for analysis and quantification. 81 
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 82 
Quantitative assessment of fluorescent intensity. DRG neurons were identified and cell bodies 83 
were selected as regions of interest (ROI) using ImageJ software (NIH). At least 200 neurons 84 
were sampled, in serial sections at a distance of at least 10 sections (i.e. 100 µm) apart. c-Fos 85 
immunoreactivity was determined by counting number of positive profiles within a region 86 
defined as laminae I and II, using Axiovision LE 4.8 software (Zeiss). Iba-1 and p-p38 87 
immunoreactivity was determined by counting number of positive profiles within three 2.25 88 
x104 µm2 boxes in laminae I-III. Knee joint sections were examined at 10x magnification to 89 
identify areas with the highest nerve fibre or cell density in the synovium. The length of nerve 90 
fibres was determined by manually tracing them from Z-stack images using Axiovision LE 4.8 91 
software (Zeiss) and reported as density of fibres per volume of synovium – area of synovium 92 
x thickness (30µm) - as described previously13. CD117+ mast cells were counted and data was 93 
expressed as density of cells per volume of synovium13.  94 
 95 
Western blotting.  RBL-2H3 cells were homogenized in lysis buffer and 30 mg/ml of protein 96 
was loaded on a 10% SDS-PAGE gel. Proteins were wet-transferred using the Bio-Rad 97 
system (Bio-Rad Laboratories) and blots were probed overnight with rabbit anti- 98 
cyclooxygenase-2 (COX-2) (1:5000; Abcam), incubated with HRP–conjugated anti-rabbit 99 
immunoglobulin (Dako) and visualised with BioSpectrum System (Ultra-Violet Products Ltd). 100 
Bands were analysed with Quantity One (Bio-Rad Laboratories). β-actin (1:1000; Cell 101 
Signaling) was used as loading control.  102 
 103 
Flow cytometry. Seven days after OA induction, the skin and muscle were removed and the 104 
knee joint isolated with care not to damage the bone and release bone marrow content. Knee 105 
joints were digested in serum-free RPMI containing collagenase D (0.5µg/ml) and DNAse 106 
(40µg/ml). Isolated cells were incubated with Fc block anti-mouse CD16/CD32 (Clone 2.4G2, 107 
BD Biosciences) followed by fluorochrome-conjugated anti-mouse antibodies: CD45.1-Pacific 108 
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Blue™ (Clone 30-F11, BioLegend), F4/80-PE (Clone BM8, eBioscience), CD11b-APC (Clone 109 
M1/70, eBioscience), CD117-PeCy7 (Clone 2B8, BioLegend) and FcƐRIα-APC eFluor 780 110 
(Clone MAR 1, eBioscience). Cells were analysed with LSRFortessa™ (BD bioscience) and 111 
analyzed with FlowJo software (Tree Start).  112 
 113 
Synovial fluid collection. The skin of the knee joint was excised; the patellar ligament was then 114 
severed below the patella, which was lifted to expose the synovial membrane. A 30-gauge 115 
needle (Micro-Fine insulin syringe; 0.3 ml) was carefully inserted into the knee joint space and 116 
gently flushed twice with 25 µl of sterile saline.  A total 50 µl of synovial lavage sample was 117 
carefully recovered, diluted 1:50 in ELISA buffer, and Prostaglandin D2 (PGD2) levels were 118 
quantified by MOX ELISA kit (Cayman Chemical, Cambridge, UK). 119 
 120 
Cell culture. Rat RBL-2H3 mast cell line (ATCC® CRL-2256™) was plated onto 12-well plates 121 
(1x106cells per well), sensitized for 16h with 100ng/ml anti-DNP IgE (Sigma-Aldrich) and then 122 
stimulated with 20ng/ml DNP-BSA (Molecular probes) and 100ng/ml rat β-NGF (R&D 123 
Systems) for 0-12h. In some experiments, cells were incubated with DNP-BSA, β-NGF 124 
together with LY311727 (Tocris), for 12h. Cell media were used for quantification of PGD2 by 125 
ELISA. 126 
 127 
Data Analysis. Data were tested for normal distribution (Shapiro–Wilk test) and analysed for 128 
statistical differences using SigmaPlot 13.0 (Systat Software). For behavioural analysis, based 129 
on our previous experience and data, in order to achieve alpha 0.05 and power 0.8 we used at 130 
least 6 animals per group. Data analysis was performed by two-way repeated measures 131 
ANOVA, followed by Tukey test. For immunohistochemical analysis, cell culture and FACS 132 
analysis, in order to achieve alpha 0.05 and power 0.8 we used at least 4 samples per group 133 
and  data were analysed by one way ANOVA followed by Tukey test. The problem of family-134 
wise error rate inflation (inherent in multiple testing) was controlled within each model using 135 
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Tukey as post-hoc procedures. Data are expressed as mean±SEM. Results were considered 136 
significant when p<0.05. 137 
 138 
 139 
Results 140 
 141 
Rapid onset of mechanical hypersensitivity and greater dorsal horn neuron activation 142 
and microglial response in the spinal cord of TrkA KI mice after intra-articular MIA 143 
 144 
We predicted that a gain in function of TrkA receptors would enhance pain-like behaviour in 145 
the MIA model and measured hind paw withdrawal thresholds to mechanical stimulation as 146 
baseline values were comparable between TrkA KI and WT mice (Fig. 1A).  Furthermore, we 147 
used a submaximal dose of MIA (0.7mg/mouse), which in WT mice was associated with slow 148 
development of ipsilateral mechanical hypersensitivity starting from day 7 and lasting for up to 149 
day 28 as compared to saline controls (Fig 1A). We observed that mechanical hypersensitivity 150 
developed more rapidly in TrkA KI and was significantly higher than in WT mice by day 3 post-151 
MIA injection (Fig 1A). Area under the curve (AUC) analysis demonstrated that withdrawal 152 
thresholds of MIA-injected TrkA KI mice were lower than WT mice thresholds between days 0 153 
and 7 (Fig. 1B) and days 21 and 28 after MIA injection (Fig. 1C).  154 
 155 
To confirm that nerve growth factor (NGF) contributed to mechanical hypersensitivity in TrkA 156 
KI mice, we administered a tanezumab-like antibody that prevented the development of 157 
mechanical hypersensitivity throughout the duration of the study (14 days) compared to 158 
vehicle treatment (Fig. 1D and E). Similarly, the antibody prevented the development of 159 
mechanical hypersensitivity in WT mice (Suppl. Fig. 1).  160 
Consistent with an increased afferent input to the dorsal horn of the spinal cord in the MIA 161 
model6, we counted more c-Fos-expressing neurons in ipsilateral laminae I-II at day 7 MIA 162 
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compared to saline (Fig. 2A, B and E). In addition, the number of c-Fos+ cells was higher in 163 
TrkA KI than WT dorsal horns (Fig. 2B, D and E). Similarly, Iba-1+ microglial cell number was 164 
higher in ipsilateral dorsal horn of MIA compared to saline WT mice (Fig. 2F, G and J) and 165 
even higher in MIA-TrkA KI dorsal horns (Fig. 2G, I and J). Furthermore, phosphorylated p38 166 
in Iba-1+microglia was significantly higher in ipsilateral dorsal horn of MIA- compared to saline-167 
treated TrkA KI mice (Fig. 2H, I and K). No contralateral microglia changes were observed in 168 
either WT or TrkA KI spinal cords (data not shown).  169 
 170 
These data indicate that the responses of central neurons and microglia to peripheral tissue 171 
injury are amplified in TrkA KI conditions and these central changes are associated with the 172 
faster on-set of OA pain-related behaviour in TrkA KI compared to WT mice. 173 
 174 
Higher number of inflammatory cells in the MIA knee joint of TrkA KI mice 175 
 176 
As we were interested in exploring novel neuro-immune mechanisms that would involve the 177 
NGF-TrkA signalling in the joint, we examined the extent of synovial inflammation, which  is 178 
associated with MIA pain phenotype more than cartilage degradation3.  179 
 180 
Indeed, 7 days after MIA injection, no signs of cartilage degradation were observed in either 181 
WT or TrkA KI joints (Fig. 3A). However, both synovial volume and density of CGRP-182 
expressing fibres were higher in MIA compared to saline groups (Fig. 3B, C, D and E). We 183 
noticed that, under normal conditions (saline-treated mice), CGRP-fibres density in TrkA KI 184 
was higher than in WT synovia (Fig. 3C, D and E). Consistent with higher expression of CGRP 185 
in peptidergic fibres9, the cell bodies of TrkA KI sensory fibres expressed more CGRP than 186 
WT fibres (Fig. 3F, G, H and I) and CGRP increased significantly 7 days after MIA injection in 187 
both WT and TrkA KI (Fig. 3F, G, H and I), suggesting that this peptide is up-regulated as a 188 
result of MIA-induced inflammation in the joints.   189 
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 190 
Although synovial fibre density and volume changes were comparable between TrkA KI and 191 
WT, flow cytometry analysis of cells isolated from the knee joints revealed that inflammatory 192 
cells numbers were not altered on day 7 after MIA injection in WT tissue, but samples of MIA-193 
TrkA KI ipsilateral joints contained a significant higher numbers of leukocytes (CD45+ cells) 194 
(Fig. 4B, D and E), macrophages (F4/80+CD11b+ cells) (Fig. 4B, D and F) and mast cells 195 
(CD117+ and FCƐRI+) (Fig. 4B, D and G).  196 
 197 
Consistent with the flow cytometry data, there were more CD117 immunoreactive cells 198 
(marker for both CD117+FCγRI+ and CD117+FCγRI- mast cells) in the synovia of MIA-TrkA KI 199 
joints than in synovia of TrkA KI saline controls (Fig 5C, D and E).  200 
 201 
No changes in mast cells numbers were observed in WT synovia between saline and MIA-202 
treated groups (Fig. 5A, B and E). Intriguingly, in the synovia of TrkA KI joints, more mast cells 203 
were located in the vicinity of CGRP-positive fibres compared to both TrkA KI saline controls 204 
and MIA WT joints (Fig. 5B, C, D and F). Thus, on day 7 after a submaximal MIA dose the 205 
cellular infiltrate reaches measurable levels in TrkA KI knee joints, which cannot be detected 206 
under WT conditions. 207 
 208 
NGF up-regulates COX-2 which mediates a delayed PGD2 formation in mast cells 209 
 210 
MIA-associated synovial inflammation is amplified under TrkA KI conditions and provides a 211 
model setting to investigate neuro-immune mechanisms that are driven by NGF. As mast cells 212 
that accumulated close to sensory fibres can express TrkA receptors, we tested the 213 
hypothesis that NGF activation of mast cells leads to the release of mediators, which can 214 
sensitise nociceptive fibres. We confirmed existing data14 and observed that NGF stimulates 215 
the generation of PGD2 in basophilic leukaemia cell line RBL-2H3, which is known to resemble 216 
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mast cells15. Specifically, 12h after antigen (DNP-BSA)-dependent stimulation, a significant 217 
increase of PGD2 levels over basal values was quantified in the media (Fig. 6A). The 218 
presence of NGF with DNP-BSA in the culture media resulted in higher PGD2 levels 8h after 219 
antigen stimulation and levels remained elevated at the 12h time-point (Fig. 6A). Thus, NGF 220 
increases FCƐRI-induced production of PGD2 in culture and we know that PLA2 is required for 221 
NGF-induced delayed PGD2 generation12. We, therefore, we tested the effect of  222 
phospholipase A2 (PLA2) inhibitor LY311727 on NGF-induced PGD2 generation, 12h after 223 
incubation - the time-point at which differences in PGD2 generation between experimental 224 
groups were more pronounced. LY311727 (1-100µM) inhibited NGF-induced PGD2 225 
generation, in a concentration-dependent manner (Fig. 6B). Indeed, when cells were 226 
stimulated with DNP-BSA and NGF, the levels of PGD2 released in the media were higher 227 
than when cells were stimulated with DNP-BSA alone (Fig. 6B). The presence of 1µM 228 
LY311727 had no effect on either DNP-BSA or DNP-BSA with NGF-induced PGD2 generation 229 
(Fig. 6B). LY311727 (10µM) had no effect on DNP-BSA induced generation of PGD2 but 230 
reduced the level of PGD2 generated by the antigen together with NGF (Fig. 6B). At 100µM, 231 
LY311727 reduced the generation of PGD2 induced by both antigen and antigen together with 232 
NGF (Fig. 6B).  233 
 234 
Whilst the initial phase of PGD2 generation is dependent on constitutively expressed COX-1, 235 
the second phase is dependent on the induction of COX-2 mRNA and protein14, 16. We, 236 
therefore, quantified COX-2 after cells were incubated with DNP-BSA alone or together with 237 
NGF and found that LY311727 (10µM) significantly reduced NGF-induced expression of COX-238 
2, but not in cells incubated with antigen alone (Fig. 6C and D). At 100µM, LY311727 reduced 239 
COX-2 protein levels in cells stimulated with either antigen alone or antigen together with NGF 240 
(Fig. 6C and D). Altogether, these results confirm that NGF induces up-regulation of COX-2 241 
that results in delayed PGD2 formation in mast cells.  242 
 243 
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PGD2 synthase inhibitor HQL-79 prevents MIA-induced mechanical hypersensitivity in 244 
TrkA KI mice 245 
 246 
PGD2 is known to exert pro-nociceptive effects through the activation of PGD2 receptor 1 247 
(DP1) and 2 (DP2) receptors expressed by sensory neurons, which potentiate the amplitude of 248 
tetrodotoxin-resistant (TTX-R) Na+ currents17. Therefore, NGF-induced production of PGD2 in 249 
mast cells could mediate the pro-nociceptive effect of NGF in TrkA KI joints in which a 250 
significant number of mast cells are located in the vicinity of sensory neurons.   To test this 251 
possibility we evaluated the effect of the PGD2 synthase inhibitor HQL-79 on MIA-induced 252 
hypersensitivity. We used an inhibitor acting downstream of the PGD2 synthesis cascade in 253 
order to avoid non-specific effects on other bioactive prostaglandins. When WT and TrkA KI 254 
mice were administered with either 3 or 10mg/kg of HQL-79 daily, for 8 days, starting from the 255 
day of the MIA injection, we observed a dose-dependent reduction of mechanical thresholds 256 
(Fig. 6E). On the last experimental day the lowest dose of HQL-79 (3mg/kg) reversed MIA-257 
induced hypersensitivity in TrkA KI, but not WT mice (Fig. 6E). However, at the higher dose of 258 
10mg/kg, HQL-79 induced similar reversal of MIA-induced mechanical hypersensitivity in TrkA 259 
KI and WT mice (Fig. 6E). Next, we evaluated whether HQL-79 treatment had affected PGD2 260 
synthesis in the damaged tissue and measured PGD2 levels in knee joints lavages.  We 261 
observed that at 7 days after MIA injection, the levels of PGD2 were significantly higher in 262 
TrkA KI than WT joint lavages (Fig 6F). After treatment with 3mg/kg of HQL-79, PGD2   joint 263 
levels were significantly lower than in vehicle treated, in TrkA KI but not in WT samples (Fig. 264 
6F). However, a higher dose of HQL-79 (10mg/kg) reduced PGD2 levels in both WT and TrkA 265 
KI joints (Fig. 6F). These data indicate that an increased production of PGD2 in the knee joint 266 
is critical for the development of mechanical hypersensitivity in TrkA KI mice. 267 
 268 
Discussion  269 
 270 
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In this study, we have identified a novel pathway that highlights the critical contribution of the 271 
NGF/TrkA system to the initiation of mechanical allodynia in a model of OA pain.  Using the 272 
TrkA KI mouse model, which amplifies changes in MIA-associated inflammation, we reveal 273 
mechanisms that could not be detected in WT conditions at the dose of MIA selected for these 274 
studies.   275 
Our in vitro findings suggest that, in OA joints, extracellular NGF acts via TrkA receptor 276 
activation in mast cells and results in significant up-regulation of COX-2 and generation of 277 
PGD2.  This prostaglandin can then sensitise sensory neurons through the activation of DP1 278 
receptors17, which facilitate noxious signalling from the OA joint to the dorsal horn of the spinal 279 
cord. Thus, this mast cell-to-nociceptors communication involves an anatomical relationship 280 
and includes PGD2 as an essential mediator in the cascade of events that acts downstream of 281 
TrkA activation on mast cells, sensitizing nociceptors via DP1 receptor activation.  The 282 
pathway described here represents a novel signalling module that underlies interactions 283 
between mast cells and nociceptive neurons in eliciting OA-pain hypersensitivity (Fig. 7). Our 284 
data indicate no occurrence of gender differences whereas significant gender variance applies 285 
to immune cell response in the spinal cord after peripheral nerve injury18. 286 
The knee joints are innervated by primary afferent fibres whose cell bodies are located in the 287 
lumbar DRG6, 19. A significant proportion of these joint afferents, in both humans and animals 288 
are peptidergic and some of them express TrkA receptors19, 20. Both CGRP and substance P 289 
(SP) are up-regulated in DRG under peripheral inflammatory conditions as well as after MIA 290 
injection in the knee, which also results in elevation of TrkA mRNA levels in DRG19, 21 .We 291 
observed that a TrkA mutation, which increases receptor signalling, is associated with a 292 
significant increase in both number of neurons and percentage of CGRP-expressing neurons 293 
in TrkA KI DRG9. Such changes can be explained by the following evidence: i) most DRG 294 
neurons depend on NGF-TrkA signalling for survival during development ; ii) null mutations of 295 
NGF and TrkA are associated with substantial loss of sensory neurons   iii) CGRP  levels in 296 
sensory neurons are under NGF regulation22.  297 
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 298 
In this study, under TrkA KI conditions, the responses to primary afferent input from the joint of 299 
both dorsal horn neurons and microglia were magnified and indicated the occurrence of 300 
central sensitization.  Indeed, MIA injection in the knee is associated with an increased 301 
release of peptides from primary afferent fibres in the dorsal horns and intrathecal CGRP 302 
antagonists can reverse established MIA referred allodynia6. Following MIA treatment, dorsal 303 
horn neurons with input from the joints demonstrate expansion of their peripheral receptive 304 
fields and intra-articular NGF injection, at a dose previously shown to produce pain behaviour, 305 
increases both responses and peripheral receptive fields of spinal neurons in untreated and, 306 
to a larger extent, in MIA-treated rats21. Together, these data suggest that engagement of the 307 
NGF/TrkA system is associated with a spinal sensitization7. Relevantly, the spreading of pain 308 
to sites distant from the joint has been reported in OA patients and central sensitisation is 309 
believed to underlie such change23, 24. 310 
 311 
There is increasing evidence that inflammation is present in synovial tissue of OA patients and 312 
synovitis is associated with pain in human OA23, 25. Extracellular NGF at the periphery acts on 313 
TrkA receptors expressed by peptidergic fibres, increasing inflammation and neuropeptide 314 
release from sensory nerves19, 26. Furthermore, intra-articular NGF can increase synovitis and 315 
the number of inflammatory cells, including macrophages and mast cells, in the synovium21. 316 
Consistently, blockade of TrkA receptor signalling reduces synovitis in MIA-induced OA3.   317 
 318 
Mast cells are elevated in joints of OA compared to rheumatoid arthritis patients suggesting a 319 
specific role of these cells in the pathophysiology of OA27. There are several mechanisms by 320 
which mast cells can contribute to the pathology of OA, namely by attracting other immune 321 
cells through cytokine and chemokine release2. Further, mast cells can contribute to pain in 322 
OA by releasing soluble mediators and enzymes2. In this study we focused on the latter 323 
mechanism, as we observed a close anatomical relationship between mast cells and 324 
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peptidergic fibres in the synovia. A similar anatomical arrangement has been reported 325 
previously whereby mast cells and peptidergic fibres form a functional unit involved in the 326 
axon reflex2. Particularly, NGF-induced inflammation in non-articular tissues involves mast cell 327 
degranulation2, 22. NGF has been suggested to exert a direct role on mast cell development 328 
and function and bone marrow derived mast cells from TrkA knock out mice show decrease 329 
degranulation in comparison to bone marrow derived mast cells from control mice28, 29. NGF 330 
can drive the synthesis of PGD214, 16, which is synthesised by COX-1 and 2, and is the main 331 
prostaglandin released by mast cells.  In this study, we observed that NGF induced PGD2 332 
production by mast cells through the induction of mast cell COX-1/2 expression. PGD2 333 
receptors, namely DP1 receptors, are expressed by nociceptive fibres, where they can 334 
increase CGRP release and bradykinin-induced SP release as well as the amplitude of TTX-R 335 
sodium currents17, 30. Here we observed that a PGD2 synthase inhibitor prevented both 336 
development of MIA-induced mechanical hypersensitivity and PGD2 accumulation in the knee 337 
joint, providing further support to a role of mast cell-derived PGD2 in modulation of nociceptive 338 
signalling.  339 
 340 
In conclusion, anti-NGF therapies have shown promising analgesic potential for OA pain 341 
treatment. However, the presence of significant adverse effects on the joint structure calls for 342 
a better understanding of the mechanisms by which NGF-TrkA signalling participate in OA 343 
pain. Here we suggest that blockade of TrkA in mast cells constitutes a potential target for OA 344 
pain.  For instance selectivity could be achieved through the development of bispecific 345 
antibodies31  where the second arm targets both TrkA and a mast cell specific antigen.  346 
 347 
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Legends 466 
 467 
Figure 1. MIA-induced mechanical hypersensitivity develops faster in TrkA KI mice. A, 468 
Mechanical thresholds assessed as paw withdrawal thresholds (PWT) following intra-articular 469 
injection of monoiodoacetate (MIA) (0.7 mg/mouse) or saline (10 µl/mouse) to wild type (WT) 470 
or TrkAP782S mice (TrkA KI). Values are mean ± SEM, n=9-12 mice/group. *p<0.05, 471 
***p<0.001 versus saline control or versus WT MIA. Two-way repeated measures (RM) 472 
ANOVA followed by post-hoc Tukey test. There is a statistically significant interaction between 473 
factors (P<0.001) B, Areas under the curve (AUC) for ipsilateral PWT from day 0 to 7 after 474 
MIA injection. C, AUC for ipsilateral PWT from days 21 to 28 after MIA injection. Values are 475 
mean ± SEM. *p<0.05, *** p<0.001, versus saline control group or versus WT MIA; one-way 476 
ANOVA post-hoc Tukey test. D, Mechanical thresholds (PWT) following intra-articular injection 477 
of MIA (0.7mg/mouse) or saline (10 µl/mouse). On days -1, 4 and 9 mice were treated with 478 
Tanezumab-like antibody (Ab) or control Ab (5mg/kg s.c.) (Sigma I5154). Values are mean  479 
±SEM of 6-9 mice/group. ***p< 0.001; **p<0.01 versus saline Tanezumab-like Ab group or 480 
versus TrkA KI MIA control Ab group. Two-way RM ANOVA post-hoc Tukey test. There is a 481 
statistically significant interaction between factors (P<0.001) E, AUC for ipsilateral PWT. 482 
Values are mean±SEM. *** p<0.001, versus saline Tanezumab-like Ab group or versus MIA 483 
control Ab group; one-way ANOVA post-hoc Tukey test.  484 
 485 
Figure 2. Greater dorsal horn neuron activation and microglia response in the lumbar spinal 486 
cord of TrkA KI mice at 7 days after MIA. A-D, c-Fos immunoreactivity in the dorsal horn Scale 487 
bar 200 µm. E, Quantification of c-Fos immunoreactivity in laminae I and II (size of area: 6x104 488 
µm2). F-I, Iba1 (red) and p-p38 (green) immunoreactivity in the ipsilateral dorsal horn. Scale 489 
bars 100 µm. J and K, Quantification of Iba1 (J) and p-p38/Iba1 (K) immunoreactivity in the 490 
ipsilateral dorsal horn (size of area: 2.25x104 µm2). Values are mean ± SEM. * p<0.05, ** 491 
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p<0.01, ***p<0.001 versus saline control or versus WT MIA, one-way ANOVA, post-hoc Tukey 492 
test. n=4-6.  493 
 494 
Figure 3. Osteoarthritis pathology and CGRP expression in DRG 7 days after MIA injection. A 495 
Quantitative scoring of osteoarthritis joint pathology B-C, Quantification of both synovial 496 
volume B) and CGRP immunopositive fibre density  (C) in MIA or saline injected joints of WT 497 
or TrkA KI mice. D-E, CGRP+ fibres in ipsilateral knee joint synovium of WT (D) and TrkA KI 498 
(E). F-G, Expression of CGRP immunoreactivity in L3 DRG of WT (F) and TrkA (G) Scale bar 499 
50 µm. H-I, Percentage of CGRP+ small (I, <21 µm) and medium (J, 21-36 µm) diameter 500 
neurons in L3 DRG. Values are mean ± SEM. *p< 0.05; **p<0.01; ***p<0.001 versus WT 501 
saline or versus TrkA KI MIA, one-way ANOVA, post-hoc Tukey test. n=4.  502 
 503 
Figure 4. Significant number of inflammatory cells in knee joint of TrkA KI mice 7 days after 504 
MIA. A-D, Representative dot-plot/FACS plots analysis of CD45+ cells  (left panels), F4/80+ 505 
and CD11b+ cells (centre panels) and CD117+ and FCƐRI+ cells  (right panels) in ipsilateral 506 
knee joints. E-G, Quantification of leukocytes (E), macrophages (F) and mast cells (G) in 507 
synovial fluid. Values are mean ± SEM; n=4-7 per experimental group. ** p<0.01 *** p<0.001 508 
versus saline control; One-way ANOVA post hoc Tukey test.  509 
 510 
Figure 5. Significant number of mast cells in vicinity of nociceptive fibres, in TrkA KI joints 7 511 
days after MIA. A-D, CD117+ cells and CGRP+ fibres in ipsilateral knee joint synovia. Scale 512 
bars 50 µm. E-F, Quantification of total number of mast cells (E) and number of mast cells in 513 
close proximity (<5 µm) to CGRP fibres (F) in synovia of MIA or saline injected joints of WT or 514 
TrkA KI mice. Values are mean ± SEM; n=4 per experimental group. *p<0.05, **p<0.01, 515 
versus control group or versus WT MIA one-way ANOVA post hoc Tukey test.  516 
 517 
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Figure 6. NGF induces PGD2 synthesis in mast cells and inhibition of PGD2 in the knee joint is 518 
associated with prevention of MIA-induced mechanical hypersensitivity.  A, Time course of 519 
PGD2 generation. RBL-2H3 cells were stimulated with DNP-BSA (20 ng/ml, black bars) or 520 
DNP-BSA with 100 ng/ml NGF (white bars). Values are mean ± SEM, n=4-8. *p<0.05, 521 
**p<0.01 ***p<0.001 versus baseline values or versus antigen alone. One-way ANOVA post-522 
hoc Tukey’s test. B-D, Effects of PLA2 inhibitor LY311727 on PGD2 generation (B) and COX-2 523 
protein levels (C-D). RBL-2H3 cells were stimulated for 12h with DNP-BSA (20 ng/ml, black 524 
bars) or DNP-BSA with 100 ng/ml NGF (white bars) in the presence of LY311727. Values are 525 
mean ± SEM, n=6. *p<0.05, *** p<0.001 compared to no PLA2 inhibitor control or versus 526 
antigen alone. E-F, Dose-dependent reversal of mechanical hypersensitivity by prolonged oral 527 
administration of HQL-79 (3 and 10 mg/kg); vehicle control 0.5% methyl-cellulose. E, 528 
Percentage reversal assessed on day 7 post-MIA injection. F, HQL-79 reduced the levels of 529 
PGD2 recovered from the synovial fluid of MIA-injected knee joints, in a dose dependent 530 
manner. Values are mean ± SEM, n=6-16. *p<0.05, ** p<0.01 compared to no inhibitor control 531 
or versus WT mice. One-way ANOVA post-hoc Tukey test.  532 
 533 
Figure 7. Proposed model describing the pathway through which PGD2 generated by mast 534 
cells in response to elevation in NGF levels leads to an increase of nociceptive signalling in 535 
OA joints. Extracellular NGF produced in response to inflammation activates TrkA receptors in 536 
mast cells and facilitates PGD2 formation in two ways i) by promoting the translocation of PLA2 537 
from cytoplasm to endoplasmic reticulum, where PLA2 releases arachidonic acid (AA) from 538 
membrane phospholipids and ii) by inducing expression of COX-2 which mediates the 539 
synthesis of PGD2 precursor PGH2 from AA. PGD2 can exert a pro-nociceptive effect through 540 
the activation of DP1 receptors expressed by sensory neurons, which activate sodium 541 
channels thereby increasing afferent input to the dorsal horn of the spinal cord. 542 
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